Abstract:As one of the most aggressive human malignancies, pancreatic cancer is a leading cause of cancer-related deaths worldwide and only about 4 % of patients will live 5 years after diagnosis. Eighty to approximately eighty-five percent of patients are diagnosed with an unresectable or metastatic disease, which is correlated with poor prognosis and low survival rate. Therefore, it is tremendously significant to exploit novel chemicals to prevent and treat pancreatic cancer. Previous research and clinical studies have demonstrated that many natural products derived from traditional Chinese medicine (TCM) such as camptothecin derivatives and vinca alkaloids could be effective antitumor compounds, hinting that TCM is a promising source for developing new antitumor drugs. In this report, we investigated the effects of bufalin, a primary active ingredient of the traditional Chinese medicine Chan-Su, on pancreatic cancer cell lines PANC-1 and CFPAC-1 and studied the underlying molecular mechanism. We found that exposure to bufalin could suppress the proliferation of pancreatic cancer cells time and dose dependently. We used flow cytometry to study the effects of bufalin on apoptosis and cell cycle distribution in PANC-1 and CFPAC-1 cells. The results indicated that bufalin could significantly induce both apoptosis and G2/M cell cycle arrest in pancreatic cancer cells. With western blotting, we found that the expression level of an antiapoptotic protein heat shock protein 27 (Hsp27) and its partner molecule p-Akt was decreased upon the treatment with bufalin. Besides, bufalin activated pro-caspase-3 and pro-caspase-9 and modulated the expression level of Bcl-2 and Bax. These data suggested that bufalin may trigger apoptosis by targeting Hsp27, which could inhibit apoptosis by interfering with key apoptotic proteins. The influence on the level of cylinB1, CDK1, and p21 was also observed after bufalin treatment, and the relationship between Hsp27 and the cell cycle-related proteins mentioned above deserves much more research. In addition, our data showed that bufalin could enhance the growth inhibition effect of gemcitabine in above pancreatic cancer cells. Taken together, bufalin might be worthy of further study for its potential as a therapeutic agent for pancreatic cancer treatment.

Bufalin Inhibits Htert Expression and Colorectal Cancer Cell Growth by Targeting CPSF4

Bufalin Inhibits HCT116 Colon Cancer Cells and Its Orthotopic Xenograft Tumor in Mice Model Through Genes Related to Apoptotic and PTEN/AKT Pathways

Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer

Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer

Bufalin targets the SRC-3/c-Myc pathway in chemoresistant cells to regulate metastasis induced by chemoresistance in colorectal cancer

Bufalin Induces Mitochondria-Dependent Apoptosis in Pancreatic and Oral Cancer Cells by Downregulating hTERT Expression via Activation of the JNK/p38 Pathway

Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways

Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells

Bufalin Inhibits NCI-H460 Human Lung Cancer Cell Metastasis in Vitro by Inhibiting MAPKs, MMPs, and NF-κB Pathways.

Bufalin attenuates the proliferation of breast cancer MCF-7 cells in vitro and in vivo by inhibiting the PI 3 K / Akt pathway

Bufalin Inhibits Gefitinib Resistant NCI-H460 Human Lung Cancer Cell Migration and Invasion in Vitro.

Inhibition Effect of Bufalin on Invasion and Metastasis of Gastric Cancer Cells

Bufalin Enhances the Anti-Proliferative Effect of Sorafenib on Human Hepatocellular Carcinoma Cells Through Downregulation of ERK

Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin

Research on the cytostatic effect of bufalin on cervical carcinoma cells and the related mechanism

Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway.

Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice

Bufalin Suppresses Hepatocellular Carcinoma Invasion and Metastasis by Targeting HIF-1α Via the PI3K/AKT/mTOR Pathway.

Bufalin Induces G0/G1 Phase Arrest Through Inhibiting the Levels of Cyclin D, Cyclin E, CDK2 and CDK4, and Triggers Apoptosis Via Mitochondrial Signaling Pathway in T24 Human Bladder Cancer Cells

Bufalin Suppresses Tumour Microenvironment-Mediated Angiogenesis by Inhibiting the STAT3 Signalling Pathway

Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling